Caricamento...
Intraokulare Entzündungen bei Brolucizumab-Anwendung: Patientenmanagement – Diagnose – Therapie
The anti-vascular endothelial growth factor (anti-VEGF) agent brolucizumab has been approved in the USA in October 2019 and in Europe in February 2020 for the treatment of neovascular age-related macular degeneration (nAMD). The approval was based on the randomized, double-blind phase III studies HA...
Salvato in:
| Pubblicato in: | Ophthalmologe |
|---|---|
| Autori principali: | , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Springer Medizin
2021
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7935813/ https://ncbi.nlm.nih.gov/pubmed/33555415 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00347-021-01321-8 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|